drugset / Trial / NCT00351949
IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Single-center, open label, non-randomized, fixed dose-escalation, phase 1 study, performed in ambulatory and day-hospital setting
Timeline
- Start
- 2005-09
- Primary completion
- 2008-08
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IMP321 | Protein / enzyme biologic | 50 ug | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 250 ug | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 1.25 mg | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 6.25 mg | Subcutaneous |
| Subject | IMP321 | Protein / enzyme biologic | 30 mg | Subcutaneous |